Anthemis hyalina for COVID-19

Anthemis hyalina may be beneficial for COVID-19 according to the studies below. COVID-19 involves the interplay of 500+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 12,000+ potential treatments. c19early.org analyzes 220+ treatments. We have not reviewed Anthemis hyalina in detail.

Protocol efficacy and cost by country

Treatment protocols varied widely

November 2026
Efficacy of protocol
SeychellesSCIcelandISBelizeBZMaltaMTLuxembourgLUMontenegroMEBhutanBTGuyanaGYComorosKMFijiFJDjiboutiDJCyprusCYMauritiusMUEstoniaEETrinidad and TobagoTTEquatorial GuineaGQBahrainBHLatviaLVGuinea-BissauGWSloveniaSINorth MacedoniaMKLesothoLSGabonGABotswanaBWGambiaGMNamibiaNALithuaniaLTAlbaniaALQatarQAJamaicaJMArmeniaAMMongoliaMNBosnia and HerzegovinaBAUruguayUYEritreaERGeorgiaGECroatiaHRPanamaPAMauritaniaMRNew ZealandNZCentral African RepublicCFIrelandIELiberiaLRCosta RicaCRNorwayNOSlovakiaSKCongoCGFinlandFIDenmarkDKSingaporeSGEl SalvadorSVKyrgyzstanKGNicaraguaNILebanonLBLibyaLYBulgariaBGParaguayPYHong KongHKSierra LeoneSLTogoTGSwitzerlandCHIsraelILSerbiaRSPapua New GuineaPGAustriaATBelarusBYTajikistanTJHungaryHUUnited Arab EmiratesAEHondurasHNSwedenSEAzerbaijanAZPortugalPTJordanJOGreeceGRCzechiaCZDominican RepublicDOSouth SudanSSCubaCUHaitiHTBelgiumBEBoliviaBOTunisiaTNBurundiBIBeninBJRwandaRWGuineaGNZimbabweZWChadTDCambodiaKHSenegalSNNetherlandsNLSyriaSYEcuadorECGuatemalaGTZambiaZMKazakhstanKZMalawiMWRomaniaROMaliMLBurkina FasoBFSri LankaLKTaiwanTWNigerNEAustraliaAUCôte d'IvoireCICameroonCMMadagascarMGVenezuelaVENepalNPYemenYEGhanaGHMozambiqueMZMalaysiaMYAngolaAOPeruPEUzbekistanUZSaudi ArabiaSAMoroccoMACanadaCAPolandPLAfghanistanAFIraqIQUkraineUASudanSDAlgeriaDZArgentinaARUgandaUGSpainESColombiaCOSouth KoreaKRKenyaKEMyanmarMMSouth AfricaZAItalyITFranceFRUKGBThailandTHGermanyDEIranIRTurkeyTRDR CongoCDVietnamVNEgyptEGPhilippinesPHEthiopiaETJapanJPMexicoMXRussiaRUBangladeshBDNigeriaNGBrazilBRPakistanPKIndonesiaIDUSAUSIndiaINChinaCNmore effective, cheaperless effective, costlier
0%20%40%60%
$0$500$1,000$1,500
Cost per course

Cost and estimated efficacy of national COVID-19 protocols; area is proportional to population. Countries are named where there is room, with more populous countries first and in darker type; hover any dot for details.

Amtaghri et al., Phytomedical compounds as promising therapeutic agents for COVID-19 targeting angiotensin-converting enzyme 2: a review, Journal of Pharmacy and Pharmacology, doi:10.1093/jpp/rgae101
Abstract Aims The aim of the present review was to highlight natural product investigations in silico and in vitro to find plants and chemicals that inhibit or stimulate angiotensin-converting enzyme 2 (ACE-2). Background The global reduction of incidents and fatalities attributable to infections with SARS-CoV-2 is one of the most public health problems. In the absence of specific therapy for coronavirus disease 2019 (COVID-19), phytocompounds generated from plant extracts may be a promising strategy worth further investigation, motivating researchers to evaluate the safety and anti-SARS-CoV-2 effectiveness of these ingredients. Objective To review phytochemicals in silico for anti-SARS-CoV-2 activity and to assess their safety and effectiveness in vitro and in vivo. Methods The present review was conducted using various scientific databases and studies on anti-SARS-CoV-2 phytochemicals were analyzed and summarized. The results obtained from the in silico screening were subjected to extraction, isolation, and purification. The in vitro studies on anti-SarcoV-2 were also included in this review. In addition, the results of this research were interpreted, analyzed, and documented on the basis of the bibliographic information obtained. Results This review discusses recent research on using natural remedies to cure or prevent COVID-19 infection. The literature analysis shows that the various herbal preparations (extracts) and purified compounds can block the replication or entrance of the virus directly to carry out their anti-SARS-CoV-2 effects. It is interesting to note that certain items can prevent SARS-CoV-2 from infecting human cells by blocking the ACE-2 receptor or the serine protease TMPRRS2. Moreover, natural substances have been demonstrated to block proteins involved in the SARS-CoV-2 life cycle, such as papain- or chymotrypsin-like proteases. Conclusion The natural products may have the potential for use singly or in combination as alternative drugs to treat/prevent COVID-19 infection, including blocking or stimulating ACE-2. In addition, their structures may provide indications for the development of anti-SARS-CoV-2 drugs.
Barış et al., Effective Fragrance Molecules and Essential Oils: A Potential Relief for COVID-19, Natural Product Communications, doi:10.1177/1934578X261487547
Objectives Essential oils and their chemical constituents are recognized for their antimicrobial properties against many infections. In this study, some molecules of essential oils are identified as potentially effective on the MPro of SARS-CoV-2 and as a BRD2 inhibitors. These essential oils were combined in an optimum formulation as (Anti-COV19-VERS4). This study evaluates the role of Anti-COV19-VERS4, in preventing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) contagiousness and its secondary effects on infected tissues by in-vivo experiments. Methods Anti-COV19-VERS4 is formulated based on molecular docking studies. Following cytotoxic and antiviral dose determination, SARS-CoV-2 infected transgenic mice were treated with Anti-COV19-VERS4 spray. RT-qPCR was used to detect viral load and histopathologic analysis was performed. The experiment was terminated on the days of 5 and 6 when SARS-CoV-2 infection peaked. RT-qPCR was used to detect viral load and histopathologic analysis was performed. Two-way ANOVA and Student’s t -tests were used for statistical analysis. Results Cytotoxicity and neutralization assays revealed that the most effective dilution of Anti-COV19-VERS4 showing cytopathic effect (CPE) was 1/2600 and the 24-hour CC50 dose was 0.0154 mg/L. During in-vivo trials, 3 out of 14 mice in the control group died due to infection. The virus load of the Anti-COV19-VERS4 spray group on day 6 decreased compared to the control group. Moreover, lung injury scores for the Anti-COV19-VERS4 spray group were significantly lower than the control group on the 6 th day (p<0.05). This study demonstrates that Anti-COV19-VERS4 may be useful for preventing the contagiousness of SARS-CoV-2 and relieving lung injury. Conclusion Anti-COV19-VERS4 may be helpful as a cost-effective and efficacious adjunctive therapy for SARS-CoV-2.